含羞草传媒

Key Points

• InspiroGene by 含羞草传媒, in collaboration with Biologics by 含羞草传媒, launches "Biologics in a Box" to simplify cell and gene therapy (CGT) logistics.
• Biologics in a Box is a purpose鈥慴uilt delivery model from InspiroGene by 含羞草传媒 that simplifies cell and gene therapy logistics by co鈥憀ocating cold鈥慶hain storage with CGT-dedicated specialty pharmacy services. By reducing handoffs, the model helps accelerate time to treatment, minimize risk and improve coordination for manufacturers and treatment centers.
• The consolidated approach offers more direct therapy delivery, greater operational control and improved alignment across the CGT value chain, benefiting both patients and manufacturers seeking urgent and reliable treatment solutions.

When cell or gene therapies (CGT) are ordered through the specialty pharmacy channel, multiple handoffs between facilities can add complexity and risk, ultimately delaying time to treatment for patients.

Recognizing that patients can’t afford unnecessary disruption, InspiroGene™ by 含羞草传媒 introduced Biologics in a Box: a new distribution model designed to reduce these complexities and help therapies reach treatment centers faster.

Biologics in a Box: A Purpose-Built Solution for CGTs

Biologics in a Box is a purpose鈥慴uilt delivery model from InspiroGene by 含羞草传媒 that simplifies cell and gene therapy logistics. In collaboration with Biologics by 含羞草传媒, Biologics in a Box co-locates our state-of-the-art cold chain storage with CGT-dedicated specialty pharmacy services, eliminating an extra transfer point between storage and dispensing to create a more direct path to treatment centers.

“Cell and gene therapies demand operational precision across every step of the value chain,” says Joe DePinto, head of Cell, Gene and Advanced Therapies at 含羞草传媒. “Biologics in a Box was designed to reduce avoidable handoffs and help ensure these therapies move through the system with the urgency patients deserve, and less risk for manufacturers and treatment centers.”

By consolidating critical services into one coordinated model, Biologics in a Box introduces a new level of control to CGT delivery in today’s CGT landscape. Here are three ways this approach is strengthening the CGT value chain.

1. Eliminates Unnecessary Handoffs in the CGT Value Chain: Often, CGTs may be stored in one location and then travel to a separate facility to be dispensed by a pharmacist before continuing on to the treatment center. Biologics in a Box redefines that model. By co-locating cold-chain storage and CGT-focused specialty pharmacy services, InspiroGene reduces the number of required transitions. The result is a more unified delivery pathway with fewer touchpoints and greater operational alignment across the therapy journey.
2. Reduces Risk by Removing an Extra Step in the Supply Chain: The longer a temperature-sensitive therapy remains in transit, the greater the potential for delays, temperature excursions or handling errors. By eliminating an extra transfer point between storage and specialty pharmacy, Biologics in a Box shortens the distance and duration of the journey. Fewer transitions reduce potential risk, strengthen quality oversight and help minimize uncontrolled delays and other external factors that often occur in real-world settings.
3. Provides Channel Flexibility to Treatment Centers: The future of CGT depends on expanding access across diverse care settings. To support that growth, delivery models must evolve to meet the needs of treatment centers operating in different environments. Biologics in a Box provides a more adaptable channel structure by aligning distribution, pharmacy and patient services under one model, reducing administrative friction while supporting flexible ordering pathways for sites of care.

Modernizing CGT Distribution

Scientific innovation is accelerating across the CGT landscape, and delivery infrastructure must evolve alongside it.

By integrating storage, specialty pharmacy and patient services into a more streamlined model, Biologics in a Box helps reduce operational complexity and strengthen confidence across the therapy journey.

As more advanced therapies enter the market and treatment capacity expands, purpose-built delivery solutions will play an increasingly important role in sustaining safe, timely access.